Patents Assigned to OYSTER POINT PHARMA, INC.
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11911380
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 27, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903943
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903941
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Compositions and use of varenicline for treating dry eye
    Patent number: 11903942
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: March 23, 2023
    Date of Patent: February 20, 2024
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
    Patent number: 11542253
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.
    Type: Grant
    Filed: January 8, 2021
    Date of Patent: January 3, 2023
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Jr., Julio A. Munoz, Pieter Albert Otten
  • Methods of increasing lacrimal proteins
    Patent number: 11224598
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: January 18, 2022
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
    Patent number: 10919879
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.
    Type: Grant
    Filed: August 14, 2019
    Date of Patent: February 16, 2021
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Jr., Julio A. Munoz, Pieter Albert Otten
  • Methods of treating ocular conditions
    Patent number: 10709707
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: July 14, 2020
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, James Loudin, Kenneth J. Mandell
  • Dry eye treatments
    Patent number: 10456396
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: October 29, 2019
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
    Patent number: 10421745
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.
    Type: Grant
    Filed: April 25, 2018
    Date of Patent: September 24, 2019
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Jr., Julio A. Munoz, Pieter Albert Otten
  • METHODS OF TREATING OCULAR CONDITIONS
    Publication number: 20190201397
    Abstract: Described herein are methods and pharmaceutical formulations for treating ocular conditions.
    Type: Application
    Filed: April 6, 2017
    Publication date: July 4, 2019
    Applicant: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael ACKERMANN, James LOUDIN, Kenneth J. MANDELL
  • Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine
    Patent number: 9981949
    Abstract: The present invention relates to the stereospecific synthesis of (R)-5-((E)-2-pyrrolidin-3-ylvinyl)pyrimidine, its salt forms, and novel polymorphic forms of these salts.
    Type: Grant
    Filed: November 17, 2016
    Date of Patent: May 29, 2018
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Srinivasa Rao Akireddy, Balwinder Singh Bhatti, Timothy J. Cuthbertson, Gary Maurice Dull, Craig Harrison Miller, Joseph Pike Mitchener, Jr., Julio A. Munoz, Pieter Albert Otten
  • Dry Eye Treatments
    Publication number: 20170239244
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Application
    Filed: February 1, 2017
    Publication date: August 24, 2017
    Applicant: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, JR., James Loudin, Kenneth J. Mandell
  • Dry eye treatments
    Patent number: 9597284
    Abstract: Described herein are methods and pharmaceutical formulations for treating dry eye disease.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: March 21, 2017
    Assignee: Oyster Point Pharma, Inc.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Methods of improving ocular discomfort
    Patent number: 9532944
    Abstract: Described herein are methods and pharmaceutical formulations for improving ocular discomfort.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: January 3, 2017
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Methods of increasing tear production
    Patent number: 9504644
    Abstract: Described herein are methods and pharmaceutical formulations for increasing tear production.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 29, 2016
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell
  • Pharmaceutical formulations for treating ocular conditions
    Patent number: 9504645
    Abstract: Described herein are pharmaceutical formulations for treating ocular conditions.
    Type: Grant
    Filed: October 19, 2015
    Date of Patent: November 29, 2016
    Assignee: OYSTER POINT PHARMA, INC.
    Inventors: Douglas Michael Ackermann, Jr., James Loudin, Kenneth J. Mandell